Study S001145

A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00976391
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 586
Start: 2009-09
Primary completion: 2011-10
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:albiglutide + insulin glargine; DRUG:insulin glargine + preprandial lispro insulin
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26 [Baseline and Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020558	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Rosenstock J, Diabetes care	2014	Randomized trial	PMID 24898300 DOI	cites ClinicalTrials.gov:NCT00976391; registry reference DERIVED:24898300